Albireo Pharma announced that its investigational new drug application, or IND, has cleared the required 30 day review by the FDA and is in effect for a Phase 2 clinical trial of elobixibat, a once-daily, orally-available ileal bile acid transporter inhibitor, for the treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.